{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-002688","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.566449+00:00","generated_at":"2026-05-16T10:57:13.223308+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"confidence":"high","headline":"Zura Bio expands HS trial to 225 patients; expects Q4 2026 data; cash through 2027","bullets":["Phase 2 TibuSHIELD trial in HS expanded from 180 to 225 participants; topline data expected Q4 2026.","Phase 2 TibuSURE trial in SSc: topline data anticipated in first half of 2027.","Cash and equivalents sufficient to fund operations through 2027, beyond both data readouts.","Tibulizumab is a first-in-class bispecific antibody targeting IL-17 and BAFF pathways."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-002688","json":"https://secwatch.observer/filing/0001104659-26-002688.json","markdown":"https://secwatch.observer/filing/0001104659-26-002688.md","text":"https://secwatch.observer/filing/0001104659-26-002688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000110465926002688/0001104659-26-002688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000110465926002688/tm262894d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:57:13.223308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}